APSR2026-90

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-002
P79
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1206191-46904-APSR2026_Poster_AntiJo1_ASS-ILD_FINAL VERSION_425777.pdf
Format: PDF Only
16. Interstitial Lung Disease
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Shan Kai Ing * Sibu Hospital Respiratory Unit, Department of Medicine, Sarawak Malaysia
Yih Hoong Lee - Sibu Hospital Respiratory Unit, Department of Medicine, Sarawak Malaysia
Gurvinderjit Singh - Sibu Hospital Respiratory Unit, Department of Medicine, Sarawak Malaysia
Jennie Geok Lim Tan - Sibu Hospital Department of Radiology Sarawak Malaysia
Chee How Liew - Sibu Hospital Rheumatology Unit, Department of Medicine Sarawak Malaysia
Guo Ruey Ling - Sibu Hospital Rheumatology Unit, Department of Medicine Sarawak Malaysia
Nga Hung Ngu - Sibu Hospital Respiratory Unit, Department of Medicine, Sarawak Malaysia
 
 
 
 
 
 
 
 
Presenting Author Details
Shan Kai
Ing
shankai1992@gmail.com
+60182107030
31-40
Malaysia
Original Research
Heterogeneous Outcomes in Anti-Jo-1 Antisynthetase Syndrome–Associated Interstitial Lung Disease: A Cohort from Sibu Hospital, Sarawak, Malaysia
Maximum 25 words
Abstract Content
Anti-synthetase syndrome (ASS) is a rare autoimmune disease frequently complicated by interstitial lung disease (ILD), which is the principal determinant of morbidity and mortality. High-resolution CT (HRCT) patterns such as non-specific interstitial pneumonia (NSIP), organising pneumonia (OP), and usual interstitial pneumonia (UIP) are associated with differing prognoses and treatment responses. We aimed to compare clinical features, HRCT phenotypes, treatment strategies, disease progression, and outcomes among three patients with anti-Jo-1 ASS-ILD managed at Sibu Hospital, Sarawak.
We conducted a retrospective descriptive case series of three adult patients diagnosed with anti-Jo-1 ASS-ILD in 2019, 2020, and 2025 at Sibu Hospital. Data collected included clinical presentation, serological profile, HRCT pattern, immunosuppressive therapy, functional status, oxygen requirement, and survival outcomes. HRCT phenotypes were categorised as NSIP, OP, or UIP. Use and timing of immunosuppressive and antifibrotic therapies were reviewed.
All three patients presented with progressive dyspnoea and were strongly positive for anti-Jo-1 antibodies. HRCT demonstrated NSIP, OP, and UIP patterns respectively. Two patients received early induction therapy with intravenous cyclophosphamide followed by mycophenolate mofetil, while one patient was initially treated with azathioprine and methotrexate prior to escalation. Despite treatment, all patients experienced recurrent disease exacerbations with progressive functional decline requiring long-term oxygen therapy. The NSIP-pattern patient survived four years from diagnosis, whereas patients with OP and UIP patterns deteriorated rapidly and died within two years. In the patient with UIP pattern, antifibrotic therapy could not be initiated in a timely manner due to resource and budgetary constraints, potentially contributing to disease progression.
This cohort from Sibu Hospital demonstrates substantial heterogeneity in anti-Jo-1 ASS-ILD outcomes according to HRCT phenotype. Progressive fibrotic patterns, particularly UIP, are associated with poor prognosis despite aggressive immunosuppression. Limited access to timely antifibrotic therapy in resource-constrained settings may further impact outcomes, underscoring the importance of early risk stratification, treatment optimisation, and referral pathways.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Antisynthetase syndrome; Interstitial lung disease; Anti-Jo-1
maximum 3 keywords and no abbreviations, separated by commas
The authors would like to thank the Director General of Health Malaysia for the permission to publish this paper.
302